IRIS
POLONI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.651
EU - Europa 5.895
AS - Asia 5.129
SA - Sud America 1.392
AF - Africa 315
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 14
AN - Antartide 1
Totale 23.416
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.477
SG - Singapore 1.577
IT - Italia 1.248
VN - Vietnam 1.180
BR - Brasile 1.094
RU - Federazione Russa 1.004
CN - Cina 822
UA - Ucraina 789
DE - Germania 504
IE - Irlanda 482
SE - Svezia 438
HK - Hong Kong 417
FR - Francia 338
TR - Turchia 335
FI - Finlandia 302
DK - Danimarca 290
GB - Regno Unito 221
KR - Corea 167
IN - India 152
CI - Costa d'Avorio 115
AR - Argentina 100
BD - Bangladesh 94
CA - Canada 77
MA - Marocco 76
NL - Olanda 69
MX - Messico 66
IQ - Iraq 63
JP - Giappone 54
PL - Polonia 48
CO - Colombia 46
ZA - Sudafrica 45
AT - Austria 41
EC - Ecuador 39
ID - Indonesia 38
VE - Venezuela 37
PK - Pakistan 31
UZ - Uzbekistan 31
ES - Italia 25
BE - Belgio 24
PY - Paraguay 24
TN - Tunisia 23
CL - Cile 21
EU - Europa 19
AE - Emirati Arabi Uniti 18
DZ - Algeria 16
PH - Filippine 16
MY - Malesia 15
PE - Perù 15
AU - Australia 13
HU - Ungheria 13
AZ - Azerbaigian 12
KE - Kenya 12
SA - Arabia Saudita 12
EG - Egitto 11
JO - Giordania 11
IL - Israele 9
UY - Uruguay 9
CH - Svizzera 8
BG - Bulgaria 7
IR - Iran 7
KZ - Kazakistan 7
TW - Taiwan 7
BH - Bahrain 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
LB - Libano 6
LT - Lituania 6
TH - Thailandia 6
AL - Albania 5
BO - Bolivia 5
NP - Nepal 5
SN - Senegal 5
HN - Honduras 4
KG - Kirghizistan 4
KW - Kuwait 4
MN - Mongolia 4
OM - Oman 4
PS - Palestinian Territory 4
RO - Romania 4
BZ - Belize 3
GA - Gabon 3
GT - Guatemala 3
HR - Croazia 3
MD - Moldavia 3
PT - Portogallo 3
EE - Estonia 2
ET - Etiopia 2
GY - Guiana 2
MT - Malta 2
PR - Porto Rico 2
QA - Qatar 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
Totale 23.391
Salva come PNG Salva come JPEG
Città #
Ashburn 1.526
Singapore 925
Jacksonville 821
Chandler 752
Fairfield 619
Dallas 593
Dublin 482
San Jose 475
Boardman 467
Hong Kong 398
Ho Chi Minh City 395
Des Moines 337
New York 336
Wilmington 331
Hanoi 272
Houston 252
Seattle 237
The Dalles 231
Woodbridge 209
Los Angeles 205
Beijing 197
Lauterbourg 195
Lawrence 182
Princeton 182
San Mateo 176
Moscow 167
Cambridge 147
Ann Arbor 129
Hefei 126
Milan 126
Helsinki 120
Abidjan 115
Chicago 113
Centro 112
São Paulo 83
Ancona 81
San Diego 78
Buffalo 74
Munich 74
Redmond 74
Council Bluffs 67
Orem 67
Turin 65
Rome 62
Da Nang 57
Haiphong 56
Marche 46
London 45
Santa Clara 44
Salt Lake City 43
Pune 41
Denver 40
Guangzhou 37
Shanghai 36
Frankfurt am Main 34
Porto 33
Tokyo 33
Warsaw 33
Nuremberg 31
Amsterdam 30
Montreal 30
Chennai 28
Phoenix 28
Norwalk 27
Pianella 27
Tashkent 27
Turku 27
Stockholm 26
Washington 26
Brooklyn 25
Johannesburg 25
Rio de Janeiro 25
Atlanta 24
Miano 23
Vienna 23
Baghdad 21
Brussels 21
Belo Horizonte 20
Biên Hòa 19
Columbus 19
Elk Grove Village 19
Naples 19
Poplar 19
Boston 18
Brasília 18
Medellín 18
Mexico City 18
Mumbai 18
Toronto 18
Hải Dương 17
Curitiba 16
Tampa 16
Can Tho 14
Falconara Marittima 14
Hangzhou 14
Lahore 14
Manchester 14
San Francisco 14
Wuhan 14
Porto Alegre 13
Totale 14.130
Salva come PNG Salva come JPEG
Nome #
The Time Has Come for Targeted Therapies for AML: Lights and Shadows 381
Algoritmi diagnostico-terapeutici in Ematologia 315
Human white adipocytes convert into “rainbow” adipocytes in vitro 263
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 221
Human de-differentiated adipocytes show similar properties to bone marrow derived mesenchymal stem cells 218
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment 211
Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells 206
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome? 202
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 192
Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. 189
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. 185
Adipocytes properties and crosstalk with immune system in obesity-related inflammation. 175
Conditioning regimen with beam plus amifostine for outpatient autologous stem cell tansplantation: feasibility and outcome in 97 lymphoma patients. 174
Glial-like differentiation potential of human mature adipocytes 169
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 167
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 165
Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes 164
Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin 162
Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. 160
A Combination of Lenalidomide and Rituximab (ReRi) As Salvage Therapy in Elderly Patients Affected By Diffuse Large B Cells (DLBCL) Lymphoma Relapsed and Refractory 159
Efficacy and feasibility of high-dose cytarabine plus idarubicin and amifostine as induction schedule: a prospective observational study of 100 AML elderly patients 158
Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis 156
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 156
Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype 154
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 153
Human bone marrow adipocytes maintain the survival and differentiation of hematopoietic stem cells 152
A real life survey on erytropoietin alpha treatment in a cohort of 1049 low risk MDS patients: an italian MDS registry study 151
Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. 150
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. 150
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. 150
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis 149
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 148
A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure 147
Bone marrow adipocytes support haematopoietic stem cell survival 146
Biosafety evidence for human dedifferentiated adipocytes 145
The exosomal surface phenotype and inflamma-miR cargo correlate with MDS diagnosis 145
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study 143
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study 142
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. 142
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 141
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 141
Bone Marrow "Yellow" and "Red" Adipocytes: Good or Bad Cells? 141
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. 140
Cytokine expression profile of selected cell populations from patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation wih reduced conditioning. 139
Human Mesenchymal Stem Cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion 139
Plasticity of human dedifferentiated adipocytes toward endothelial cells 138
High predictive value of the revised international prognostic scoring system (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry 137
Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study 137
LATE EFFECTS IN Hodgkin's POPULATION Treated BETWEEN 1980-2005 IN A SINGLE INSTITUTION 137
A rare case of aCML associated with CNS involvement and with aggressive clinical course 137
Hematologic reconstitution after PBPC autotransplantation:comparison between programmed-rate freezing and uncontrolled freezing at –80° 136
Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate 135
MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells 134
Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography 133
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. 132
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 130
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 130
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 129
LA POSITIVITÀ DEL WT1 POST-INDUZIONE È UN IMPORTANTE FATTORE PROGNOSTICO PREDITTIVO DI RECIDIVA PRECOCE IN UNA CASISTICA DI 80 PAZIENTI AFFETTI DA LEUCEMIA ACUTA MIELOIDE 128
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell trasplantation 127
Hematologic reconstitution after PBPC autotransplantation: comparison between programmed-rate freezing and uncontrolled-rate freezing at -80 degrees C 127
Targeting the immune system in MDS and MPN: Understanding the immunome and response to immunotherapy - Part 2 126
Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes 125
Molecular and functional characterization of human bone marrow adipocytes 125
History and scientific production of clinica medica and clinica ematologica in ancona 124
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 123
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 122
Bone Marrow Adipose Tissue 122
Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS) 121
Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation 121
Novel Translational Read-Through–Inducing Drugs as A Therapeutic Option for Shwachman-Diamond Syndrome 120
Patients with chronic extensive GvHD produce high levels of stimulatory auto-antibodies to the PDGF receptor: a new pathophysiological pathway of the disease progression 119
Identification of different adypocytes populations within human marrow microenvironment 117
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 117
Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow 116
Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. 116
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 116
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems 116
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 114
AMIFOSTINE CAN REDUCE MUCOSAL DAMAGE AFTER HIGH-DOSE MELPHALANCONDITIONING FOR PERIPHERAL BLOOD PROGENITOR CELL AUTOTRANSPLANT: A RETROSPECTIVE STUDY. EFFECT OF AMIFOSTINE ON MUCOSITIS DURING AUTOLOGOUS PBPC TRANSPLANTATION 113
Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. 112
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study 112
CHANGES IN RPS14 EXPRESSION LEVELS DURING LENALIDOMIDE TREATMENT IN LOW- AND INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITH CHROMOSOME 5Q DELETION 110
Mesenchymal stem cells of myelodysplastic syndromes show impaired hematopoietic support function and global DNA hypermethylation status 110
Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society 110
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 109
Assessment and monitoring of CMV infection in patients receiving a reduced-intensity conditioning allogeneic transplant: comparison of antigenaemia assay with quantitative PCR 108
A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study 108
DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype 107
Long duration of response to azacitidine in MDS. Multicenter retrospective study of 36 patients 106
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 105
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome 105
VERY LOW TOXICITY AND GOOD QUALITY OF LIFE IN 48 ELDERLY PATIENTS AUTOTRANSPLANTED FOR HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE 104
Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells 103
TREATMENT WITH AZACITIDINE REVERSES MESENCHYMAL STEM CELLS DERIVED FROM HIGH RISK MYELODYSPLASTIC PATIENTS TO A NORMAL PHENOTYPE 103
Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. 102
Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q) 102
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME 102
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 101
QUALITY OF LIFE ASSESSMENT IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME 100
Totale 14.275
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.726
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.726
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021124 0 0 0 0 0 0 0 0 0 0 0 124
2021/20221.467 72 351 26 90 10 80 68 111 91 131 136 301
2022/20232.479 225 241 208 188 155 516 2 120 584 10 184 46
2023/20241.626 228 49 87 233 254 371 42 35 5 56 33 233
2024/20253.608 357 318 141 61 131 101 305 101 859 262 338 634
2025/20269.409 630 737 687 1.054 892 658 1.703 933 734 730 296 355
Totale 23.947